These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 35982681)

  • 1. Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources.
    Sullivan DJ; Franchini M; Joyner MJ; Casadevall A; Focosi D
    medRxiv; 2022 Aug; ():. PubMed ID: 35982681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources.
    Sullivan DJ; Franchini M; Joyner MJ; Casadevall A; Focosi D
    Nat Commun; 2022 Oct; 13(1):6478. PubMed ID: 36309490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1.
    Sullivan DJ; Franchini M; Senefeld JW; Joyner MJ; Casadevall A; Focosi D
    J Gen Virol; 2023 May; 104(5):. PubMed ID: 37167085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays.
    Seidel A; Hoffmann S; Jahrsdörfer B; Körper S; Ludwig C; Vieweg C; Albers D; von Maltitz P; Müller R; Lotfi R; Wuchter P; Klüter H; Kirchhoff F; Schmidt M; Münch J; Schrezenmeier H
    Front Immunol; 2023; 14():1170759. PubMed ID: 37180152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-titer post-vaccine COVID-19 convalescent plasma for immunocompromised patients during the first omicron surge.
    Tayyar R; Wong LK; Dahlen A; Shu E; Pandey S; Liu AY
    Transpl Infect Dis; 2023 Apr; 25(2):e14055. PubMed ID: 36929619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diminished Neutralization Capacity of SARS-CoV-2 Omicron BA.1 in Donor Plasma Collected from January to March 2021.
    Lin YJ; Evans DH; Robbins NF; Orjuela G; Abe KT; Rathod B; Colwill K; Gingras AC; Tuite A; Yi QL; O'Brien SF; Drews SJ
    Microbiol Spectr; 2023 Aug; 11(4):e0525622. PubMed ID: 37289096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Viral Specific Antibody Convalescent Plasma Effectively Neutralizes SARS-CoV-2 Variants of Concern.
    Li M; Beck EJ; Laeyendecker O; Eby Y; Tobian AA; Caturegli P; Wouters C; Chiklis GR; Block W; McKie R; Joyner M; Wiltshire TD; Dietz AB; Gniadek TJ; Shapiro A; Yarava A; Lane K; Hanley D; Bloch EM; Shoham S; Cachay ER; Meisenberg BR; Huaman MA; Fukuta Y; Patel B; Heath SL; Levine AC; Paxton JH; Anjan S; Gerber JM; Gebo KA; Casadevall A; Pekosz A; Sullivan DJ;
    medRxiv; 2022 Mar; ():. PubMed ID: 35262085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralizing antibody levels against SARS-CoV-2 variants of concern Delta and Omicron in vaccine breakthrough-infected blood donors.
    Franchini M; Focosi D; Mengoli C; Percivalle E; Sammartino JC; Ferrari A; Zani M; Glingani C; Baldanti F
    Transfusion; 2022 Jun; 62(6):1171-1176. PubMed ID: 35426131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone.
    Santos da Silva E; Servais JY; Kohnen M; Arendt V; Gilson G; Staub T; Seguin-Devaux C; Perez-Bercoff D
    Curr Issues Mol Biol; 2023 Feb; 45(2):1741-1761. PubMed ID: 36826057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.
    Harvala H; Nguyen D; Simmonds P; Lamikanra AA; Tsang HP; Otter A; Maes P; Webster M; Clarkson A; Kaloyirou F; Hopkins V; Laidlaw SM; Carroll M; Mora A; Griffiths A; MacLennan S; Estcourt L; Roberts DJ
    Transfusion; 2022 Jul; 62(7):1347-1354. PubMed ID: 35588314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
    Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
    Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
    Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
    Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1.
    Sullivan DJ; Franchini M; Senefeld JW; Joyner MJ; Casadevall A; Focosi D
    bioRxiv; 2022 Dec; ():. PubMed ID: 36482971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.
    Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Couto CIC; Güler A; Mampilli V; Schmitt GJ; Mottl J; Ziegenhals T; Fesser S; Reinholz J; Wernig F; Schraut KG; Hefesha H; Cai H; Yang Q; Walzer KC; Grosser J; Strauss S; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Kohmer N; Ciesek S; Swanson KA; Vogel AB; Türeci Ö; Sahin U
    Sci Immunol; 2022 Dec; 7(78):eade9888. PubMed ID: 36378074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection.
    Kurhade C; Zou J; Xia H; Liu M; Yang Q; Cutler M; Cooper D; Muik A; Sahin U; Jansen KU; Ren P; Xie X; Swanson KA; Shi PY
    Emerg Microbes Infect; 2022 Dec; 11(1):1828-1832. PubMed ID: 35792746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced neutralizing antibody potency of COVID-19 convalescent vaccinated plasma against SARS-CoV-2 Omicron variant.
    Gallian P; Amroun A; Laperche S; Le Cam S; Brisbarre N; Malard L; Nurtop E; Isnard C; Richard P; Morel P; Tiberghien P; de Lamballerie X
    Vox Sang; 2022 Jul; 117(7):971-975. PubMed ID: 35577569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern.
    Li M; Beck EJ; Laeyendecker O; Eby Y; Tobian AAR; Caturegli P; Wouters C; Chiklis GR; Block W; McKie RO; Joyner MJ; Wiltshire TD; Dietz AB; Gniadek TJ; Shapiro AJ; Yarava A; Lane K; Hanley DF; Bloch EM; Shoham S; Cachay ER; Meisenberg BR; Huaman MA; Fukuta Y; Patel B; Heath SL; Levine AC; Paxton JH; Anjan S; Gerber JM; Gebo KA; Casadevall A; Pekosz A; Sullivan DJ
    Blood Adv; 2022 Jun; 6(12):3678-3683. PubMed ID: 35443020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing antibody responses in vaccinated and unvaccinated individuals infected with Omicron BA.1 variant.
    Oh SJ; O SW; Choi YJ; Kim JM; Kim D; Kim IH; Park AK; Kim HM; Rhee JE; Jang YR; Yoo CK; Kim JY; Kim EJ
    J Clin Virol; 2022 Oct; 155():105253. PubMed ID: 35988369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses.
    Branche AR; Rouphael NG; Diemert DJ; Falsey AR; Losada C; Baden LR; Frey SE; Whitaker JA; Little SJ; Anderson EJ; Walter EB; Novak RM; Rupp R; Jackson LA; Babu TM; Kottkamp AC; Luetkemeyer AF; Immergluck LC; Presti RM; Bäcker M; Winokur PL; Mahgoub SM; Goepfert PA; Fusco DN; Malkin E; Bethony JM; Walsh EE; Graciaa DS; Samaha H; Sherman AC; Walsh SR; Abate G; Oikonomopoulou Z; El Sahly HM; Martin TCS; Rostad CA; Smith MJ; Ladner BG; Porterfield L; Dunstan M; Wald A; Davis T; Atmar RL; Mulligan MJ; Lyke KE; Posavad CM; Meagher MA; Stephens DS; Neuzil KM; Abebe K; Hill H; Albert J; Lewis TC; Giebeig LA; Eaton A; Netzl A; Wilks SH; Türeli S; Makhene M; Crandon S; Lee M; Nayak SU; Montefiori DC; Makowski M; Smith DJ; Roberts PC; Beigel JH;
    medRxiv; 2022 Jul; ():. PubMed ID: 35898343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.